Actriib-mfc
Actriib-mfc has been studied in 1 paper since 2011: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Feb 1, 2011: “Inhibition of activin receptor type IIB increases strength and lifespan in myotubularin-deficient mice”.
1 paper studies it3 findingsUpdated
See all 1 papers on actriib-mfc
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Joshua Frase Foundation and 2 more
- 3 of 3 findings with company ties
- Animals1
What did studies of actriib-mfc find?
3Studies of actriib-mfc measured 3 outcomes: type 2b myofiber hypertrophy, forelimb grip strength and lifespan.
Type 2b myofiber hypertrophy
upin mice1
1 study
Type 2b myofiber hypertrophy
upin mice1
Actriib-mfc increases type 2b myofiber hypertrophy in mice (restricted to type 2b myofibers).
“ActRIIB-mFC produced marked hypertrophy restricted to type 2b myofibers”
Animalsrestricted to type 2b myofibersskeletal muscle
The American journal of pathology
Forelimb grip strength
upin mice1
1 study
Forelimb grip strength
upin mice1
Actriib-mfc increases forelimb grip strength in mice (transient increase during treatment of Mtm1δ4 mice).
“with transient increases in weight, forelimb grip strength, and myofiber size”
Animalstransient increase during treatment of Mtm1δ4 mice
The American journal of pathology
Lifespan
upin mice1+17% extension
1 study
Lifespan
upin mice1+17% extension
Actriib-mfc extends lifespan in myotubularin-deficient Mtm1δ4 mice (17% extension).
“Treatment of Mtm1δ4 mice with ActRIIB-mFC produced a 17% extension of lifespan”
Animalsin myotubularin-deficient Mtm1δ4 mice
The American journal of pathology